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Abstract 
The purpose of the research was the identification of association of organs and 
systems damage in Sjogren’s syndrome with the presence of organ-specific and organ-
nonspecific autoantibodies. 
On the basis of complex examination of 21 patients with Sjogren’s syndrome (women 
age 53,5 ± 0,9 years old) and content determination of wide spectrum of organ-specific and 
organ-nonspecific autoantibodies we estimated the existence of association between presence 
of these autoantibodies and clinical manifestations of Sjogren’s syndrome. The received 
results demonstrate the relationship between the expressiveness of inflammatory 
manifestations and the content of antibodies to DNA. The expressiveness of salivary glands 
injuries is associated with content of autoantibodies to salivary glands. The presence of 
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associated diseases is also associated with existence of particular autoantibodies. As in all 
examined patients with Sjogren’s syndrome was present the digestive tract pathology, it can 
be assumed that changes in digestive tract wall lead to damage of immune system structures 
and polyclonal uncontrollable activation of antibodies production. 
Key words: Sjogren’s syndrome, organ-specific autoantibodies, organ-nonspecific 
autoantibodies, clinical features 
 
In modern medicine there is a rather extensive group of diseases where the presence of 
autobodies  is considered as a pathogenetic sign or diagnostic criterion. The development of 
autoimmune processes in these diseases is associated with features of organs’ damage as the 
list of autoantibodies is rather limited for each disease. The presence of organ-specific anti-
nuclear antibodies (ANA) is characteristic of system lupus erythematous, the presence of 
rheumatoid factor (RF) – an antibody to Fc-fragment of IgG, antibodies to cyclic citrullinated 
peptide (CCP) and vimentin - are characteristic of rheumatoid arthritis. The presence of 
organ-specific antibodies to mitochondria is characteristic of Hashimoto thyreoiditis and 
primary biliary cirrhosis, and the first one is also characteristic of presence of antibodies to 
thyroid gland antigens (thyroglobulin, microsomes, thyroperoxydase) [5, 15, 16, 22]. 
Primary Sjogren’s syndrome (SjS) holds a special place among autoimmune diseases. 
Primary SjS is an organ-specific disease of external secretion organs (salivary, lacrimal, 
digestive tract glands). Clinical manifestations of external secretion glands damage are the 
dryness of eyes, mouth, nose, throat, airways, vagina [18, 19]. Development of these clinical 
manifestations is connected with the activation of immune system cells, firstly of B-
lymphocytes and increasing in autoantibodies production by several clones of antibody-
producers [8]. 
In different countries the prevalence of SjS is from 4 to 250 cases on 100 thousand 
population, mainly women suffer over the age of 40 [1, 7, 20]. 
Numerous researchers of SjS note the presence in blood of ANA (SS A/Ro and SS 
B/La), RF, organ-specific autoantibodies which are characteristic of systemic scleroderma and 
systemic lupus erythematous, autoantibodies to thyroid gland antigens. This phenomenon is 
connected with polyclonal activation of antibody-producer cells because of immunological 
tolerance disorder [10, 12, 13, 21]. In some cases it can lead to development of non-
Hodgkin’s lymphoma, the risk of its development in patients with SjS is 44 times higher, than 
in the general population [2, 6, 7, 9, 11]. 
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The presence of organ-specific and organ-nonspecific autoantibodies in patients with 
SjS is accompanied by damage of different organs and systems besides glands of external 
secretion. However the interrelation of organ damage with a range and character of 
autoantibodies demands further clarification. 
Based on the above the purpose of research was the identification of association of 
organs and systems in SjS with the presence of various organ-specific and organ-nonspecific 
autoantibodies in this group of patients. 
Materials and methods  
21 patients with Sjogren’s syndrome were examined, all women, average age 53,5 ± 
0,9 years old. The clinical and laboratory examination included the examination by 
stomatologist, ophthalmologist, rheumatologist, neurologist, endocrinologist, 
otorhinolaryngologist, Schirmer’s test performing, determination of speed of non-stimulated 
salivation, general clinical analyses, determination of the general protein and its fractions 
content, glucose, bilirubin, AsAT, AlAT, GGTP, ALP, creatinine, identification of 
cryoglobulins, C-reactive protein (CRP), thyrotropic hormone (TSH), hormones of thyroid 
gland – thyroxine (T4) and triiodothyronine (T3). Also we determined the existence and 
content of rheumatoid factor (RF), antibodies (AB) to cyclic citrullinated peptide (CCP), 
antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), verification of 
ANA and ANCA in its existence, antibodies to gastric parietal cells and antigens of thyroid 
gland (microsomes, thyroperoxedase, thyreoglobulin), antibodies to salivary glands (using 
tissue sections of monkey’s salivary gland) and to alpha- fodrin Ig A and Ig G. As a control 
group for studying of antibodies prevalence to tissue of salivary glands and to α-fodrin were 
serums of 21 women with rheumatoid arthritis, with the ANA negative test – screening, and 
with a normal speed of salivation. Sjogren’s syndrome was diagnosed on the basis of SICCA 
criteria (Sjogren's International Collaborative Clinical Alliance, 2012) [10]. 
The received results were processed with methods of mathematical statistics using the 
Microsoft Exel software package. 
Results and their discussion  
The clinical examination of the patients included in this research revealed that 100% 
of patients complained of dryness in a mouth, difficulty of swallowing of dry food, 95% of 
patients complained of dryness of eyes, feeling of sand in eyes. On objective examination we 
revealed parenchymatous sialadenitis, keratoconjunctivitis, cheilitis. Speed of salivation 
decreased to less than 0,2 ± 0,01 ml/min. At the same time in 81,1% of patients recurrent 
parotitises were revealed, and in 95,0% of patients - dry rhinopharyngitis, that is in all patients 
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the pathology of external secretion glands was revealed. On this background in 85,7% of 
patients was periodic arthralgia. Besides, in different patients of the examined group were the 
pathological processes associated with autoimmune reactions: the regional lymphadenopathy, 
cryoglobulin purpura, Reynaud's syndrome, serositis, autoimmune thyroiditis and others. It 
should be noted especially that in 80,9% of examined patients was damage of digestive tract 
in different clinical forms. As it is considered that 70% of structural formations of the immune 
system are located in digestive tract walls, it is possible to believe that long-term damages of 
this system create preconditions for development of polyorganic autoimmune pathologies.  
More detailed examination of oral cavity revealed that all patients had cervical caries, 
in 95,2% - partial adentia, in 4,8% - total adentia. 100% of patients had dry, hyperemic 
mucous membrane of oral cavity, in 95,2% of patients were painful cracks in the mouth 
angles, in 90,5% of patients - erosions of oral mucous membranes, and in 9,5% of patients 
was severe damage – "the burning mouth". The Green-Vermillion index of oral cavity 
hygiene was 5,4± 0,1 (unsatisfactory hygiene of oral cavity). The average tear production in 
the Schirmer’s test was 5,5±0,05 ml/ 5 mines (is significantly decreased). In all patients we 
observed the changes in protein spectrum of blood with increasing in average ESR up to 25± 
0,8 mm/hour.  
The determination of organ-specific and organ-nonspecific autoantibodies content in 
blood revealed significant changes of these indicators. Results of research are shown in Table 
1. According to table data, in majority of patients was increasing in content of ANA SSA, RF, 
antibodies to thyroid gland antigens, to salivary glands, to α–fodrin of the classes IgA and 
IgG. In smaller part of examined group was increased content of autoantibodies to single- and 
double-helix DNA and antibodies to smooth muscles (SMA). Increasing in content of 
antibodies to mitochondria, microsomes, gastric parietal cells and kidney glomeruli were 
observed in certain patients. Generally it is possible to note the expressed activation of 
antibodies production in examined patients. 
The used methods of determination of content of antibodies to salivary glands showed 
sensitivity of 95%, specificity of 90,5%; to α–fodrin Ig A -sensitivity of 90%, specificity of 
85,7%; to Ig G - sensitivity of 47,6%, specificity of 71,4%. Therefore, the existence of 
antibodies to salivary glands and α–fodrin IgA – sensitive and specific sign of SjS and can be 
used as diagnostic (pathogenetic significant) criterion of SjS on early stages of disease 
progressing. The existence of antibodies to α–fodrin Ig G is less sensitive and specific sign of 
SjS that demands further researches for specification of diagnostic significant levels of these 
antibodies and their place in diagnostics of Sjogren’s syndrome. 
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Table 1  
The presence of autoantibodies and associated clinical features in Sjogren’s syndrome 
№ Characteristic of 
autoantibodies 
Number of patients 
with their presence 
(abs./%) 
Clinical features 
1. Antinuclear antibodies (АNА)  20 (95,2%)  
2. SS - A 17 (81%)  
3 SS - B 9 (42,5%)  
4. AB to double-spiral DNA  
(dsDNA) 
2 (9,5%) High activity of disease  
5. AB to single-spiral DNA  
(ssDNA) 
4 (19,0%) High activity of disease 
6. Anti-mitochondrial AB 
(AMA)-M2 
2 (9,5%) Increased level of ALP, 
AsAT, AlAT 
7. RF 16 (76,2%) Arthralgias and arthritis  
8. AB to ССР 2 (9,5%) Arthralgias and arthritis 
9. AB to gastric parietal cells  1 (5%) Atrophic gastritis, hemolytic 
anemia  
10. AB to smooth muscles (SMA) 8 (38,1%) Arthralgias, increased level of 
AsAT, AlAT, GGTP  
11. ANCA 
AB to glomerular basal 
membrane (anti -GBM) 
1 (5%) Transient proteinuria 
12. AB to thyroid gland antigens   
total 
17 (80,9%) In 8 patients – hypothyreosis  
13. AB to thyroperoxedase  13 (61,9%)  
14. AB to microsomes  4 (19%)  
15. AB to thyroglobulin   7 (33,3%)  
16. AB to salivary glands  20(95,2%)  
17. AB to alpha–fodrin Ig A 19(90,5%)  
18. AB to alpha–fodrin Ig G 10 (47,6%)  
 
In the comparative analysis of clinical features of SjS and autoantibodies spectrum 
certain associations were revealed. In patients with maximum activity of inflammatory 
process the existence of rather large number of antibodies to single- and double-helix DNA 
was observed. Patients complained of arthralgias, they had high level of RF, antibodies to 
CCP, however the morning joint stiffness did not exceed 40 minutes, and rheumatoid arthritis 
changes of skeletal and articular system were not revealed, so it can be assumed that patients 
had the autoimmune reaction without development of clinical pathology. In patients with 
increased activity of AlAT, AsAT, GGTP and ALP (cytolysis and cholestasis syndrome) anti-
mitochondrial antibodies M2 (AMA M2) and antibodies to smooth muscles (SMA) were 
defined. In patients with thyroiditis the increasing in content of antibodies to thyroperoxedase, 
thyroglobulin and microsomes were defined. In patient with transient proteinuria was 
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increased content of antibodies to glomerular basal membrane, in patient with atrophic 
gastritis and hemolytic anemia – increased content of antibodies to gastric parietal cells. It is 
necessary to highlight that all above-mentioned pathological processes were in patients with 
Sjogren’s syndrome, the disorder of antibodies production in all of them has the wide 
spectrum. 
Thus, the obtained data testify to existence of wide spectrum of organ-specific and 
organ-nonspecific autoantibodies associated with polyclonal uncontrollable activation of 
antibodies production in patients with Sjogren’s syndrome. As all examined patients had 
pathologies of digestive tract, it can be assumed that damage of immune system structures of 
digestive tract wall is present that leads to disorder of antibodies production and development 
of autoimmune pathology – Sjogren’s syndrome. At the same time the spectrum width of 
antibodies production disorder defines the accession of other diseases with autoimmune 
component. 
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